Cardiomyopathy

Welcome to our featured section on cardiomyopathy

This educational hub pulls together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub will be CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos.

In this section

Review Articles
Clinical publications
Guidelines

Supported through an educational grant from Bristol Myers Squibb.

Featured Articles Article icon

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines
2020 AHA/ACC guideline for the diagnosis and treatment of patients with…

Published:

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Mavacamten for treatment of symptomatic obstructive hypertrophic…

Published:

Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic
Incidence of stress cardiomyopathy during the coronavirus disease 2019…

Published:

Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis
Risk of chronic cardiomyopathy among patients with the acute phase or…

Published:

Review Articles

Contemporary application of cardiovascular magnetic resonance imaging

Han Y, Chen Y, Ferrari VA. Annu Rev Med 2020;71:221–34.

Epsilon waves in biventricular arrythmogenic cardiomyopathy

Lezcano Gort LE, Kounka Z, Roque Rodríguez B. Ann Emerg Med 2020;76:583–5.

Hypertrophic cardiomyopathy: is a 'cure' coming . . . or is it already here?

Maron BJ, Rowin EJ, Maron MS. Am J Med 2020;133:886–8.

Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy

Spoladore R, Fragasso G, Pannone L, et al. Expert Opin Pharmacother 2020;21:233–42.

Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: a systematic review

Chery G, Kamp N, Kosinski AS, et al. Am Heart J 2020;229:52–60.

Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?

European Cardiology Review 2020;15:e11.

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Role of T1 Mapping in Inherited Cardiomyopathies

European Cardiology Review 2016;11(2):96–101

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2017;6(2):63–8.

Subclinical Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

US Cardiology Review 2016;10(2):75–7

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes

Arrhythmia & Electrophysiology Review 2016;5(2):90–101

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):188–96

The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):197–202

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy

Interventional Cardiology Review 2014;9(2):108-14

Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies

Arrhythmia & Electrophysiology Review 2013;2(1):36-40

Troponin in Non-ischaemic Dilated Cardiomyopathy

European Cardiology 2011;7(3):220–4

Diagnosis and Management of Cardiomyopathies - A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

European Cardiology 2011;7(3):225–9

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Left Ventricular Non-compaction Cardiomyopathy

American Heart Hospital Journal 2010;8(2):122–4

Myocardial Perfusion Imaging in Hypertrophic Cardiomyopathy

American Heart Hospital Journal 2010;8(2):103–4

Inherited Channelopathies and Cardiomyopathies - When Is Invasive Risk Stratification Needed?

Asia-Pacific Cardiology 2011;3(1):64-6

Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

European Cardiovascular Disease 2007;3(2):88–91

Clinical publications

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink JR, Diaz R, Felker GM, et al. N Engl J Med 2021;384:105–16.

Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Papadakis M, Basu J, Sharma S. Lancet 2020;396:736–7.

Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction

Rowin EJ, Maron BJ, Carrick RT, et al. J Am Coll Cardiol 2020;75:3033–43.

Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers

Lorenzini M, Norrish G, Field E, et al. J Am Coll Cardiol 2020;76:550–9.

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

Ho CY, Mealiffe ME, Bach RG, et al. J Am Coll Cardiol 2020;75:2649–60.

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry

Neubauer S, Kolm P, Ho CY, et al. J Am Coll Cardiol 2019;74:2333–45.

Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram

Ko WY, Siontis KC, Attia ZI, et al. J Am Coll Cardiol 2020;75:722–33.

Association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement

Bandyopadhyay D, Chakraborty S, Amgai B, et al. JAMA Netw Open 2020;3:e1921669.

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

Damy T, Garcia-Pavia P, Hanna M, et al. Eur J Heart Fail 2020; epub ahead of press.

Biventricular pacemaker therapy improves exercise capacity in patients with non‐obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise

Ahmed I, Loudon BL, Abozguia K, et al. Eur J Heart Fail 2020;22:1263–72.

Advanced imaging insights in apical hypertrophic cardiomyopathy

Hughes RK, Knott KD, Malcolmson J, et al. JACC Cardiovasc Imaging 2020;13:624–30.

Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study

Pelliccia A, Caselli S, Pelliccia M, et al. Br J Sports Med 2020;54:1008–12.

Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Norrish G, Ding T, Field E, et al. JAMA Cardiol 2019;4:918–27.

Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy

Eberly LA, Day SM, Ashley EA, et al. JAMA Cardiol 2020;5:83–91.

Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population

Lorenzini M, Anastasiou Z, O’Mahony C, et al. JAMA Cardiol 2020;5:73–80.

Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy

Fumagalli C, Maurizi N, Day SM, et al. JAMA Cardiol 2020;5:65–72.

Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance

Fonseca AC, Marto JP, Pimenta D, et al. Neurology 2020;94:e107–13.

Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy

Ho CY, Olivotto I, Jacoby D, et al. Circ Heart Fail 2020;13.

Risk stratification in cardiomyopathy

Sinagra G, Carriere C, Clemenza F, et al. Eur J Prev Cardiol 2020;27:52–8.

Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system

Thomas A, Papoutsidakis N, Spatz E, et al. J Am Heart Assoc 2020;9.

Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy

Liao H, Wang Z, Zhao L, et al. Sci Rep 2020;10:17026.

Left ventricular global function index by magnetic resonance imaging — a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy

Huang S, Xu HY, Diao KY, et al. Sci Rep 2020;10:4707.

Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry

Frommeyer G, Reinke F, Andresen D, et al. Clin Res Cardiol 2020;109:508–12.

Hypertrophic cardiomyopathy - a heterogeneous and lifelong disease in the real world

Kitaoka H, Kubo T, Doi YL. Circ J 2020;84:1218–26.

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy

Geske JB, Driver CN, Yogeswaran V, et al. Am Heart J 2020;221:159–64.

Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy

Lu DY, Ventoulis I, Liu H, et al. Am Heart J 2020;219:58–69.

Guidelines

Clarification of the Australian heart failure guideline recommendation for primary prevention defibrillator implantation in non‐ischaemic cardiomyopathy

Kistler PM, Atherton JJ, Jennings G. Med J Aust 2020;212:509–510.e1.

Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association

Musunuru K, Hershberger RE, Day SM, et al. Circ Genom Precis Med 2020;13:e000067.

Contemporary application of cardiovascular magnetic resonance imaging

Han Y, Chen Y, Ferrari VA. Annu Rev Med 2020;71:221–34.

Epsilon waves in biventricular arrythmogenic cardiomyopathy

Lezcano Gort LE, Kounka Z, Roque Rodríguez B. Ann Emerg Med 2020;76:583–5.

Hypertrophic cardiomyopathy: is a 'cure' coming . . . or is it already here?

Maron BJ, Rowin EJ, Maron MS. Am J Med 2020;133:886–8.

Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy

Spoladore R, Fragasso G, Pannone L, et al. Expert Opin Pharmacother 2020;21:233–42.

Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: a systematic review

Chery G, Kamp N, Kosinski AS, et al. Am Heart J 2020;229:52–60.

Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?

European Cardiology Review 2020;15:e11.

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Role of T1 Mapping in Inherited Cardiomyopathies

European Cardiology Review 2016;11(2):96–101

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2017;6(2):63–8.

Subclinical Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

US Cardiology Review 2016;10(2):75–7

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes

Arrhythmia & Electrophysiology Review 2016;5(2):90–101

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):188–96

The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):197–202

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy

Interventional Cardiology Review 2014;9(2):108-14

Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies

Arrhythmia & Electrophysiology Review 2013;2(1):36-40

Troponin in Non-ischaemic Dilated Cardiomyopathy

European Cardiology 2011;7(3):220–4

Diagnosis and Management of Cardiomyopathies - A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

European Cardiology 2011;7(3):225–9

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Left Ventricular Non-compaction Cardiomyopathy

American Heart Hospital Journal 2010;8(2):122–4

Myocardial Perfusion Imaging in Hypertrophic Cardiomyopathy

American Heart Hospital Journal 2010;8(2):103–4

Inherited Channelopathies and Cardiomyopathies - When Is Invasive Risk Stratification Needed?

Asia-Pacific Cardiology 2011;3(1):64-6

Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

European Cardiovascular Disease 2007;3(2):88–91

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink JR, Diaz R, Felker GM, et al. N Engl J Med 2021;384:105–16.

Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Papadakis M, Basu J, Sharma S. Lancet 2020;396:736–7.

Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction

Rowin EJ, Maron BJ, Carrick RT, et al. J Am Coll Cardiol 2020;75:3033–43.

Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers

Lorenzini M, Norrish G, Field E, et al. J Am Coll Cardiol 2020;76:550–9.

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

Ho CY, Mealiffe ME, Bach RG, et al. J Am Coll Cardiol 2020;75:2649–60.

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry

Neubauer S, Kolm P, Ho CY, et al. J Am Coll Cardiol 2019;74:2333–45.

Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram

Ko WY, Siontis KC, Attia ZI, et al. J Am Coll Cardiol 2020;75:722–33.

Association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement

Bandyopadhyay D, Chakraborty S, Amgai B, et al. JAMA Netw Open 2020;3:e1921669.

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

Damy T, Garcia-Pavia P, Hanna M, et al. Eur J Heart Fail 2020; epub ahead of press.

Biventricular pacemaker therapy improves exercise capacity in patients with non‐obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise

Ahmed I, Loudon BL, Abozguia K, et al. Eur J Heart Fail 2020;22:1263–72.

Advanced imaging insights in apical hypertrophic cardiomyopathy

Hughes RK, Knott KD, Malcolmson J, et al. JACC Cardiovasc Imaging 2020;13:624–30.

Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study

Pelliccia A, Caselli S, Pelliccia M, et al. Br J Sports Med 2020;54:1008–12.

Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Norrish G, Ding T, Field E, et al. JAMA Cardiol 2019;4:918–27.

Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy

Eberly LA, Day SM, Ashley EA, et al. JAMA Cardiol 2020;5:83–91.

Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population

Lorenzini M, Anastasiou Z, O’Mahony C, et al. JAMA Cardiol 2020;5:73–80.

Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy

Fumagalli C, Maurizi N, Day SM, et al. JAMA Cardiol 2020;5:65–72.

Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance

Fonseca AC, Marto JP, Pimenta D, et al. Neurology 2020;94:e107–13.

Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy

Ho CY, Olivotto I, Jacoby D, et al. Circ Heart Fail 2020;13.

Risk stratification in cardiomyopathy

Sinagra G, Carriere C, Clemenza F, et al. Eur J Prev Cardiol 2020;27:52–8.

Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system

Thomas A, Papoutsidakis N, Spatz E, et al. J Am Heart Assoc 2020;9.

Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy

Liao H, Wang Z, Zhao L, et al. Sci Rep 2020;10:17026.

Left ventricular global function index by magnetic resonance imaging — a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy

Huang S, Xu HY, Diao KY, et al. Sci Rep 2020;10:4707.

Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry

Frommeyer G, Reinke F, Andresen D, et al. Clin Res Cardiol 2020;109:508–12.

Hypertrophic cardiomyopathy - a heterogeneous and lifelong disease in the real world

Kitaoka H, Kubo T, Doi YL. Circ J 2020;84:1218–26.

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy

Geske JB, Driver CN, Yogeswaran V, et al. Am Heart J 2020;221:159–64.

Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy

Lu DY, Ventoulis I, Liu H, et al. Am Heart J 2020;219:58–69.